{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T04:56:04Z","timestamp":1790139364423,"version":"4.0.1"},"reference-count":267,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82421002"],"award-info":[{"award-number":["82421002"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82403392"],"award-info":[{"award-number":["82403392"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017367","name":"Research Fund for Young Star of Science and Technology in Shaanxi Province","doi-asserted-by":"publisher","award":["2026RC-KJXX-030"],"award-info":[{"award-number":["2026RC-KJXX-030"]}],"id":[{"id":"10.13039\/100017367","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100018537","name":"National Science and Technology Major Project","doi-asserted-by":"publisher","award":["2025ZD1800300"],"award-info":[{"award-number":["2025ZD1800300"]}],"id":[{"id":"10.13039\/501100018537","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100018537","name":"National Science and Technology Major Project","doi-asserted-by":"publisher","award":["2023ZD0510500"],"award-info":[{"award-number":["2023ZD0510500"]}],"id":[{"id":"10.13039\/501100018537","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100018537","name":"National Science and Technology Major Project","doi-asserted-by":"publisher","award":["2023ZD0501400"],"award-info":[{"award-number":["2023ZD0501400"]}],"id":[{"id":"10.13039\/501100018537","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007547","name":"Fourth Military Medical University","doi-asserted-by":"publisher","award":["2026NCRCDDPT02"],"award-info":[{"award-number":["2026NCRCDDPT02"]}],"id":[{"id":"10.13039\/501100007547","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007547","name":"Fourth Military Medical University","doi-asserted-by":"publisher","award":["2026NCRCDDPT04"],"award-info":[{"award-number":["2026NCRCDDPT04"]}],"id":[{"id":"10.13039\/501100007547","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Letters"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.canlet.2026.218803","type":"journal-article","created":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T14:53:54Z","timestamp":1787756034000},"page":"218803","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Myeloid-derived suppressor cells in the tumor microenvironment: cellular crosstalk, immunosuppressive effects, and therapeutic targets."],"prefix":"10.1016","author":[{"given":"Lisichen","family":"Zhu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sihan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daiming","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaojie","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoliang","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongzhan","family":"Nie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.canlet.2026.218803_bib1","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.canlet.2026.218803_bib2","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbcan.2026.189536","article-title":"Precision cytokine modulation to overcome tumor microenvironment-driven resistance to immune checkpoint blockade","volume":"1881","author":"Wang","year":"2026","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"10.1016\/j.canlet.2026.218803_bib3","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1158\/2326-6066.CIR-16-0297","article-title":"Myeloid-Derived Suppressor Cells","volume":"5","author":"Gabrilovich","year":"2017","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.canlet.2026.218803_bib4","doi-asserted-by":"crossref","first-page":"783","DOI":"10.3389\/fimmu.2020.00783","article-title":"Targeting Myeloid-Derived Suppressor Cell, a Promising Strategy to Overcome Resistance to Immune Checkpoint Inhibitors","volume":"11","author":"Hou","year":"2020","journal-title":"Front Immunol"},{"key":"10.1016\/j.canlet.2026.218803_bib5","article-title":"Roles of the Exosomes Derived From Myeloid-Derived Suppressor Cells in Tumor Immunity and Cancer Progression","volume":"13","author":"Chen","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.canlet.2026.218803_bib6","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.adi2952","article-title":"Tumor-associated NK cells drive MDSC-mediated tumor immune tolerance through the IL-6\/STAT3 axis","volume":"16","author":"Neo","year":"2024","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.canlet.2026.218803_bib7","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0018534","article-title":"Rgs2 mediates pro-angiogenic function of myeloid derived suppressor cells in the tumor microenvironment via upregulation of MCP-1","volume":"6","author":"Boelte","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.canlet.2026.218803_bib8","doi-asserted-by":"crossref","first-page":"114554","DOI":"10.18632\/oncotarget.23020","article-title":"CXCR2(+) MDSCs promote breast cancer progression by inducing EMT and activated T cell exhaustion","volume":"8","author":"Zhu","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.canlet.2026.218803_bib9","article-title":"Granulocytic Myeloid-Derived Suppressor Cells Promote the Stemness of Colorectal Cancer Cells through Exosomal S100A9","volume":"6","author":"Wang","year":"2019","journal-title":"Adv Sci (Weinh)"},{"key":"10.1016\/j.canlet.2026.218803_bib10","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1038\/s41571-023-00846-y","article-title":"Myeloid-derived suppressor cells in cancer and cancer therapy","volume":"21","author":"Lasser","year":"2024","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.canlet.2026.218803_bib11","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s12943-024-02208-3","article-title":"Myeloid-derived suppressor cells (MDSCs) in the tumor microenvironment and their targeting in cancer therapy","volume":"24","author":"He","year":"2025","journal-title":"Mol Cancer"},{"key":"10.1016\/j.canlet.2026.218803_bib12","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms12150","article-title":"Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards","volume":"7","author":"Bronte","year":"2016","journal-title":"Nat Commun"},{"key":"10.1016\/j.canlet.2026.218803_bib13","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1038\/s41577-020-00490-y","article-title":"Myeloid-derived suppressor cells in the era of increasing myeloid cell diversity","volume":"21","author":"Veglia","year":"2021","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.canlet.2026.218803_bib14","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.3390\/cancers17132251","article-title":"Myeloid-Derived Suppressor Cells (MDSCs) at the Crossroad of Senescence and Cancer","volume":"17","author":"Talarico","year":"2025","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.canlet.2026.218803_bib15","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/j.immuni.2021.04.004","article-title":"MDSC: Markers, development, states, and unaddressed complexity","volume":"54","author":"Hegde","year":"2021","journal-title":"Immunity"},{"key":"10.1016\/j.canlet.2026.218803_bib16","doi-asserted-by":"crossref","first-page":"51","DOI":"10.3390\/cells9010051","article-title":"Distinct Role of CD11b(+)Ly6G(-)Ly6C(-) Myeloid-Derived Cells on the Progression of the Primary Tumor and Therapy-Associated Recurrent Brain Tumor","volume":"9","author":"Wu","year":"2020","journal-title":"Cells"},{"key":"10.1016\/j.canlet.2026.218803_bib17","doi-asserted-by":"crossref","first-page":"3356","DOI":"10.1172\/JCI80005","article-title":"Myeloid-derived suppressor cells in the tumor microenvironment: expect the unexpected","volume":"125","author":"Marvel","year":"2015","journal-title":"J Clin Invest"},{"key":"10.1016\/j.canlet.2026.218803_bib18","doi-asserted-by":"crossref","first-page":"203","DOI":"10.4049\/jimmunol.0903573","article-title":"CD49d is a new marker for distinct myeloid-derived suppressor cell subpopulations in mice","volume":"185","author":"Haile","year":"2010","journal-title":"J Immunol"},{"key":"10.1016\/j.canlet.2026.218803_bib19","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1186\/s12943-022-01657-y","article-title":"Myeloid-derived suppressor cells: an emerging target for anticancer immunotherapy","volume":"21","author":"Wu","year":"2022","journal-title":"Mol Cancer"},{"key":"10.1016\/j.canlet.2026.218803_bib20","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1186\/1479-5876-9-90","article-title":"Functional characterization of human CD33+ and CD11b+ myeloid-derived suppressor cell subsets induced from peripheral blood mononuclear cells co-cultured with a diverse set of human tumor cell lines","volume":"9","author":"Lechner","year":"2011","journal-title":"J Transl Med"},{"key":"10.1016\/j.canlet.2026.218803_bib21","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.aaf8943","article-title":"Lectin-type oxidized LDL receptor-1 distinguishes population of human polymorphonuclear myeloid-derived suppressor cells in cancer patients","volume":"1","author":"Condamine","year":"2016","journal-title":"Sci Immunol"},{"key":"10.1016\/j.canlet.2026.218803_bib22","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1111\/j.1365-2567.2012.03566.x","article-title":"S100A9 a new marker for monocytic human myeloid-derived suppressor cells","volume":"136","author":"Zhao","year":"2012","journal-title":"Immunology"},{"key":"10.1016\/j.canlet.2026.218803_bib23","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1007\/s00262-015-1782-5","article-title":"Toward harmonized phenotyping of human myeloid-derived suppressor cells by flow cytometry: results from an interim study","volume":"65","author":"Mandruzzato","year":"2016","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.canlet.2026.218803_bib24","doi-asserted-by":"crossref","first-page":"5694","DOI":"10.1038\/s41467-024-49916-4","article-title":"Single-cell resolution characterization of myeloid-derived cell states with implication in cancer outcome","volume":"15","author":"Guimaraes","year":"2024","journal-title":"Nat Commun"},{"key":"10.1016\/j.canlet.2026.218803_bib25","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.aay6017","article-title":"Defining the emergence of myeloid-derived suppressor cells in breast cancer using single-cell transcriptomics","volume":"5","author":"Alshetaiwi","year":"2020","journal-title":"Sci Immunol"},{"key":"10.1016\/j.canlet.2026.218803_bib26","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20201803","article-title":"Analysis of classical neutrophils and polymorphonuclear myeloid-derived suppressor cells in cancer patients and tumor-bearing mice","volume":"218","author":"Veglia","year":"2021","journal-title":"J Exp Med"},{"key":"10.1016\/j.canlet.2026.218803_bib27","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1038\/nmeth.4380","article-title":"Simultaneous epitope and transcriptome measurement in single cells","volume":"14","author":"Stoeckius","year":"2017","journal-title":"Nat Methods"},{"key":"10.1016\/j.canlet.2026.218803_bib28","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1097\/SHK.0000000000001671","article-title":"Single-Cell RNA-seq of Human Myeloid-Derived Suppressor Cells in Late Sepsis Reveals Multiple Subsets With Unique Transcriptional Responses: A Pilot Study","volume":"55","author":"Darden","year":"2021","journal-title":"Shock"},{"key":"10.1016\/j.canlet.2026.218803_bib29","doi-asserted-by":"crossref","first-page":"9949","DOI":"10.1038\/s41467-024-54364-1","article-title":"Single cell and spatial transcriptomics highlight the interaction of club-like cells with immunosuppressive myeloid cells in prostate cancer","volume":"15","author":"Kiviaho","year":"2024","journal-title":"Nat Commun"},{"key":"10.1016\/j.canlet.2026.218803_bib30","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.molimm.2019.11.014","article-title":"Chemokines and their receptors promoting the recruitment of myeloid-derived suppressor cells into the tumor","volume":"117","author":"Li","year":"2020","journal-title":"Mol Immunol"},{"key":"10.1016\/j.canlet.2026.218803_bib31","doi-asserted-by":"crossref","first-page":"3599","DOI":"10.3390\/ijms21103599","article-title":"Understanding the Differentiation, Expansion, Recruitment and Suppressive Activities of Myeloid-Derived Suppressor Cells in Cancers","volume":"21","author":"Lim","year":"2020","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.canlet.2026.218803_bib32","doi-asserted-by":"crossref","first-page":"3655","DOI":"10.1158\/0008-5472.CAN-16-3199","article-title":"CXCL1 is critical for premetastatic niche formation and metastasis in colorectal cancer","volume":"77","author":"Wang","year":"2017","journal-title":"Cancer Res"},{"key":"10.1016\/j.canlet.2026.218803_bib33","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1016\/j.ymthe.2025.02.002","article-title":"Overcoming immunotherapy resistance in hepatocellular carcinoma by targeting myeloid IL-8\/CXCR2 signaling","volume":"33","author":"Kwong","year":"2025","journal-title":"Mol Ther"},{"key":"10.1016\/j.canlet.2026.218803_bib34","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.148960","article-title":"Resident stroma-secreted chemokine CCL2 governs myeloid-derived suppressor cells in the tumor microenvironment","volume":"7","author":"Oo","year":"2022","journal-title":"JCI Insight"},{"key":"10.1016\/j.canlet.2026.218803_bib35","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1158\/0008-5472.CAN-11-1792","article-title":"Monocytic CCR2(+) myeloid-derived suppressor cells promote immune escape by limiting activated CD8 T-cell infiltration into the tumor microenvironment","volume":"72","author":"Lesokhin","year":"2012","journal-title":"Cancer Res"},{"key":"10.1016\/j.canlet.2026.218803_bib36","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2024.2338965","article-title":"CCR2 and CCR5 co-inhibition modulates immunosuppressive myeloid milieu in glioma and synergizes with anti-PD-1 therapy","volume":"13","author":"Pant","year":"2024","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.canlet.2026.218803_bib37","doi-asserted-by":"crossref","DOI":"10.1016\/j.imbio.2021.152165","article-title":"Interleukin-1beta triggers the expansion of circulating granulocytic myeloid-derived suppressor cell subset dependent on Erk1\/2 activation","volume":"227","author":"Shi","year":"2022","journal-title":"Immunobiology"},{"key":"10.1016\/j.canlet.2026.218803_bib38","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.3390\/cancers11081120","article-title":"Cancer-Derived VEGF-C Increases Chemokine Production in Lymphatic Endothelial Cells to Promote CXCR2-Dependent Cancer Invasion and MDSC Recruitment","volume":"11","author":"Chen","year":"2019","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.canlet.2026.218803_bib39","doi-asserted-by":"crossref","first-page":"4666","DOI":"10.4049\/jimmunol.181.7.4666","article-title":"Proinflammatory S100 proteins regulate the accumulation of myeloid-derived suppressor cells","volume":"181","author":"Sinha","year":"2008","journal-title":"J Immunol"},{"key":"10.1016\/j.canlet.2026.218803_bib40","article-title":"Complement C3 of tumor-derived extracellular vesicles promotes metastasis of RCC via recruitment of immunosuppressive myeloid cells","volume":"122","author":"Zhang","year":"2025","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.canlet.2026.218803_bib41","doi-asserted-by":"crossref","DOI":"10.1016\/j.cellimm.2020.104254","article-title":"IL-6 as a major regulator of MDSC activity and possible target for cancer immunotherapy","volume":"359","author":"Weber","year":"2021","journal-title":"Cell Immunol"},{"key":"10.1016\/j.canlet.2026.218803_bib42","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2000915118","article-title":"Targeting tumor-derived NLRP3 reduces melanoma progression by limiting MDSCs expansion","volume":"118","author":"Tengesdal","year":"2021","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.canlet.2026.218803_bib43","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1002\/eji.200939903","article-title":"Hierarchy of immunosuppressive strength among myeloid-derived suppressor cell subsets is determined by GM-CSF","volume":"40","author":"Dolcetti","year":"2010","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.canlet.2026.218803_bib44","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-000949","article-title":"IL-6 regulates CCR5 expression and immunosuppressive capacity of MDSC in murine melanoma","volume":"8","author":"Weber","year":"2020","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.canlet.2026.218803_bib45","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1038\/s41416-019-0725-x","article-title":"Anti-VEGF therapy resistance in ovarian cancer is caused by GM-CSF-induced myeloid-derived suppressor cell recruitment","volume":"122","author":"Horikawa","year":"2020","journal-title":"Br J Cancer"},{"key":"10.1016\/j.canlet.2026.218803_bib46","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.598877","article-title":"Augmenting Anticancer Immunity Through Combined Targeting of Angiogenic and PD-1\/PD-L1 Pathways: Challenges and Opportunities","volume":"11","author":"Hack","year":"2020","journal-title":"Front Immunol"},{"key":"10.1016\/j.canlet.2026.218803_bib47","doi-asserted-by":"crossref","first-page":"2138","DOI":"10.1182\/blood-2003-01-0190","article-title":"Myeloid cell expansion elicited by the progression of spontaneous mammary carcinomas in c-erbB-2 transgenic BALB\/c mice suppresses immune reactivity","volume":"102","author":"Melani","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2026.218803_bib48","doi-asserted-by":"crossref","DOI":"10.1111\/sji.13107","article-title":"IL-6 is associated with expansion of myeloid-derived suppressor cells and enhanced immunosuppression in pancreatic adenocarcinoma patients","volume":"94","author":"Sharma","year":"2021","journal-title":"Scand J Immunol"},{"key":"10.1016\/j.canlet.2026.218803_bib49","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.3389\/fonc.2019.01223","article-title":"IL-6 and IL-8 Are Linked With Myeloid-Derived Suppressor Cell Accumulation and Correlate With Poor Clinical Outcomes in Melanoma Patients","volume":"9","author":"Tobin","year":"2019","journal-title":"Front Oncol"},{"key":"10.1016\/j.canlet.2026.218803_bib50","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2024.107521","article-title":"EVA1B facilitates esophageal squamous carcinoma progression and recruitment of immunosuppressive myeloid-derived suppressor cells in the tumor microenvironment","volume":"210","author":"Xia","year":"2024","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.canlet.2026.218803_bib51","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1038\/nrc3818","article-title":"Revisiting STAT3 signalling in cancer: new and unexpected biological functions","volume":"14","author":"Yu","year":"2014","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.canlet.2026.218803_bib52","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-010612","article-title":"Cell-intrinsic PD-L1 signaling drives immunosuppression by myeloid-derived suppressor cells through IL-6\/Jak\/Stat3 in PD-L1-high lung cancer","volume":"13","author":"Jeong","year":"2025","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.canlet.2026.218803_bib53","doi-asserted-by":"crossref","first-page":"9525","DOI":"10.1158\/0008-5472.CAN-05-0529","article-title":"Regulation of dendritic cell differentiation and antitumor immune response in cancer by pharmacologic-selective inhibition of the janus-activated kinase 2\/signal transducers and activators of transcription 3 pathway","volume":"65","author":"Nefedova","year":"2005","journal-title":"Cancer Res"},{"key":"10.1016\/j.canlet.2026.218803_bib54","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.1084\/jem.20080132","article-title":"Inhibition of dendritic cell differentiation and accumulation of myeloid-derived suppressor cells in cancer is regulated by S100A9 protein","volume":"205","author":"Cheng","year":"2008","journal-title":"J Exp Med"},{"key":"10.1016\/j.canlet.2026.218803_bib55","doi-asserted-by":"crossref","first-page":"4595","DOI":"10.1172\/JCI67580","article-title":"Induction of myelodysplasia by myeloid-derived suppressor cells","volume":"123","author":"Chen","year":"2013","journal-title":"J Clin Invest"},{"key":"10.1016\/j.canlet.2026.218803_bib56","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1158\/2326-6066.CIR-18-0108","article-title":"Lnc-C\/EBP\u03b2 Negatively Regulates the Suppressive Function of Myeloid-Derived Suppressor Cells","volume":"6","author":"Gao","year":"2018","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.canlet.2026.218803_bib57","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.molimm.2017.09.008","article-title":"Expression of C\/EBP\u03b2 in myeloid progenitors during sepsis promotes immunosuppression","volume":"91","author":"Dai","year":"2017","journal-title":"Mol Immunol"},{"key":"10.1016\/j.canlet.2026.218803_bib58","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.cmet.2018.04.022","article-title":"Aerobic Glycolysis Controls Myeloid-Derived Suppressor Cells and Tumor Immunity via a Specific CEBPB Isoform in Triple-Negative Breast Cancer","volume":"28","author":"Li","year":"2018","journal-title":"Cell Metab"},{"key":"10.1016\/j.canlet.2026.218803_bib59","doi-asserted-by":"crossref","first-page":"2439","DOI":"10.1084\/jem.20100587","article-title":"HIF-1\u03b1 regulates function and differentiation of myeloid-derived suppressor cells in the tumor microenvironment","volume":"207","author":"Corzo","year":"2010","journal-title":"J Exp Med"},{"key":"10.1016\/j.canlet.2026.218803_bib60","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1038\/nri2506","article-title":"Myeloid-derived suppressor cells as regulators of the immune system","volume":"9","author":"Gabrilovich","year":"2009","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.canlet.2026.218803_bib61","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/1471-2121-13-18","article-title":"Immunosuppressive activity enhances central carbon metabolism and bioenergetics in myeloid-derived suppressor cells in vitro models","volume":"13","author":"Hammami","year":"2012","journal-title":"BMC Cell Biol"},{"key":"10.1016\/j.canlet.2026.218803_bib62","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2025.218209","article-title":"Lactic acid promotes an MDSC-like phenotype via HIF1\u03b1 stabilization with impact on prognosis in renal cell carcinoma","volume":"639","author":"Babl","year":"2026","journal-title":"Cancer Lett"},{"key":"10.1016\/j.canlet.2026.218803_bib63","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1038\/s41586-019-1118-2","article-title":"Fatty acid transport protein 2 reprograms neutrophils in cancer","volume":"569","author":"Veglia","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.canlet.2026.218803_bib64","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1084\/jem.20050715","article-title":"Arginase I in myeloid suppressor cells is induced by COX-2 in lung carcinoma","volume":"202","author":"Rodriguez","year":"2005","journal-title":"J Exp Med"},{"key":"10.1016\/j.canlet.2026.218803_bib65","doi-asserted-by":"crossref","first-page":"2874","DOI":"10.1158\/0008-5472.CAN-19-2843","article-title":"Tumor-Derived Prostaglandin E2 Promotes p50 NF-\u03baB-Dependent Differentiation of Monocytic MDSCs","volume":"80","author":"Porta","year":"2020","journal-title":"Cancer Res"},{"key":"10.1016\/j.canlet.2026.218803_bib66","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/s40364-020-00201-8","article-title":"Roles of HMGB1 in regulating myeloid-derived suppressor cells in the tumor microenvironment","volume":"8","author":"Jin","year":"2020","journal-title":"Biomark Res"},{"key":"10.1016\/j.canlet.2026.218803_bib67","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2016.1196312","article-title":"Improving cancer immunotherapy by targeting the STATe of MDSCs","volume":"5","author":"de Haas","year":"2016","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.canlet.2026.218803_bib68","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.3389\/fimmu.2017.01565","article-title":"Intracellular S100A9 Promotes Myeloid-Derived Suppressor Cells during Late Sepsis","volume":"8","author":"Dai","year":"2017","journal-title":"Front Immunol"},{"key":"10.1016\/j.canlet.2026.218803_bib69","doi-asserted-by":"crossref","first-page":"11094","DOI":"10.18632\/oncotarget.7150","article-title":"Loss of oncogenic miR-155 in tumor cells promotes tumor growth by enhancing C\/EBP-\u03b2-mediated MDSC infiltration","volume":"7","author":"Kim","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.canlet.2026.218803_bib70","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1002\/ijc.32781","article-title":"STAT1 inhibits T-cell exhaustion and myeloid derived suppressor cell accumulation to promote antitumor immune responses in head and neck squamous cell carcinoma","volume":"146","author":"Ryan","year":"2020","journal-title":"Int J Cancer"},{"key":"10.1016\/j.canlet.2026.218803_bib71","doi-asserted-by":"crossref","DOI":"10.4161\/onci.25125","article-title":"Novel function of STAT1 in breast cancer","volume":"2","author":"Zhang","year":"2013","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.canlet.2026.218803_bib72","doi-asserted-by":"crossref","first-page":"6120","DOI":"10.4049\/jimmunol.1101225","article-title":"Adenosinergic regulation of the expansion and immunosuppressive activity of CD11b+Gr1+ cells","volume":"187","author":"Ryzhov","year":"2011","journal-title":"J Immunol"},{"key":"10.1016\/j.canlet.2026.218803_bib73","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/j.ccr.2008.10.011","article-title":"Overexpression of interleukin-1beta induces gastric inflammation and cancer and mobilizes myeloid-derived suppressor cells in mice","volume":"14","author":"Tu","year":"2008","journal-title":"Cancer Cell"},{"key":"10.1016\/j.canlet.2026.218803_bib74","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1038\/nrc3581","article-title":"History of myeloid-derived suppressor cells","volume":"13","author":"Talmadge","year":"2013","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.canlet.2026.218803_bib75","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1182\/blood-2006-06-031856","article-title":"L-arginine availability regulates T-lymphocyte cell-cycle progression","volume":"109","author":"Rodriguez","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2026.218803_bib76","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1038\/nm1609","article-title":"Altered recognition of antigen is a mechanism of CD8+ T cell tolerance in cancer","volume":"13","author":"Nagaraj","year":"2007","journal-title":"Nat Med"},{"key":"10.1016\/j.canlet.2026.218803_bib77","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1158\/0008-5472.CAN-17-2460","article-title":"Metformin-Induced Reduction of CD39 and CD73 Blocks Myeloid-Derived Suppressor Cell Activity in Patients with Ovarian Cancer","volume":"78","author":"Li","year":"2018","journal-title":"Cancer Res"},{"key":"10.1016\/j.canlet.2026.218803_bib78","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.adg3736","article-title":"Monocytic MDSCs exhibit superior immune suppression via adenosine and depletion of adenosine improves efficacy of immunotherapy","volume":"9","author":"Sarkar","year":"2023","journal-title":"Sci Adv"},{"key":"10.1016\/j.canlet.2026.218803_bib79","doi-asserted-by":"crossref","first-page":"2245","DOI":"10.1158\/0008-5472.CAN-09-3109","article-title":"CD73 on tumor cells impairs antitumor T-cell responses: a novel mechanism of tumor-induced immune suppression","volume":"70","author":"Jin","year":"2010","journal-title":"Cancer Res"},{"key":"10.1016\/j.canlet.2026.218803_bib80","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.ccell.2016.06.025","article-title":"Co-inhibition of CD73 and A2AR Adenosine Signaling Improves Anti-tumor Immune Responses","volume":"30","author":"Young","year":"2016","journal-title":"Cancer Cell"},{"key":"10.1016\/j.canlet.2026.218803_bib81","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1038\/s41590-020-0666-9","article-title":"Regulatory myeloid cells paralyze T cells through cell-cell transfer of the metabolite methylglyoxal","volume":"21","author":"Baumann","year":"2020","journal-title":"Nat Immunol"},{"key":"10.1016\/j.canlet.2026.218803_bib82","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1007\/s00262-018-2269-y","article-title":"Apoptosis of tumor-infiltrating T lymphocytes: a new immune checkpoint mechanism","volume":"68","author":"Zhu","year":"2019","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.canlet.2026.218803_bib83","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-007802","article-title":"MDSCs-derived GPR84 induces CD8(+) T-cell senescence via p53 activation to suppress the antitumor response","volume":"11","author":"Liu","year":"2023","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.canlet.2026.218803_bib84","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-007983","article-title":"Sulforaphane activates CD8(+) T cells antitumor response through IL-12RB2\/MMP3\/FasL-induced MDSCs apoptosis","volume":"12","author":"Liu","year":"2024","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.canlet.2026.218803_bib85","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1038\/s41416-018-0333-1","article-title":"Immunosuppression mediated by myeloid-derived suppressor cells (MDSCs) during tumour progression","volume":"120","author":"Groth","year":"2019","journal-title":"Br J Cancer"},{"key":"10.1016\/j.canlet.2026.218803_bib86","doi-asserted-by":"crossref","first-page":"210","DOI":"10.3390\/cancers13020210","article-title":"The Functional Crosstalk between Myeloid-Derived Suppressor Cells and Regulatory T Cells within the Immunosuppressive Tumor Microenvironment","volume":"13","author":"Haist","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.canlet.2026.218803_bib87","doi-asserted-by":"crossref","first-page":"5381","DOI":"10.1182\/blood-2010-11-321752","article-title":"Myeloid-derived suppressor cells express the death receptor Fas and apoptose in response to T cell-expressed FasL","volume":"117","author":"Sinha","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2026.218803_bib88","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.18632\/oncotarget.6662","article-title":"Activated T cells sustain myeloid-derived suppressor cell-mediated immune suppression","volume":"7","author":"Pinton","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.canlet.2026.218803_bib89","article-title":"Dual roles of innate immune cells and cytokines in shaping the breast cancer microenvironment","volume":"16","author":"Zhang","year":"2025","journal-title":"Front Immunol"},{"key":"10.1016\/j.canlet.2026.218803_bib90","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1158\/1078-0432.CCR-17-0691","article-title":"Nitric Oxide Production by Myeloid-Derived Suppressor Cells Plays a Role in Impairing Fc Receptor-Mediated Natural Killer Cell Function","volume":"24","author":"Stiff","year":"2018","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.canlet.2026.218803_bib91","doi-asserted-by":"crossref","first-page":"4096","DOI":"10.1158\/1078-0432.CCR-14-0635","article-title":"Inhibition of tumor-derived prostaglandin-e2 blocks the induction of myeloid-derived suppressor cells and recovers natural killer cell activity","volume":"20","author":"Mao","year":"2014","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.canlet.2026.218803_bib92","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.638841","article-title":"Interaction Between MDSC and NK Cells in Solid and Hematological Malignancies: Impact on HSCT","volume":"12","author":"Tumino","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.canlet.2026.218803_bib93","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1158\/1078-0432.CCR-19-2625","article-title":"Inhibition of MDSC Trafficking with SX-682, a CXCR1\/2 Inhibitor, Enhances NK-Cell Immunotherapy in Head and Neck Cancer Models","volume":"26","author":"Greene","year":"2020","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.canlet.2026.218803_bib94","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1158\/2326-6066.CIR-24-0775","article-title":"Trabectedin Enhances the Antitumor Effects of IL-12 in Triple-Negative Breast Cancer","volume":"13","author":"Schwarz","year":"2025","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.canlet.2026.218803_bib95","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1158\/2326-6066.CIR-17-0273","article-title":"TUSC2 Immunogene Therapy Synergizes with Anti-PD-1 through Enhanced Proliferation and Infiltration of Natural Killer Cells in Syngeneic Kras-Mutant Mouse Lung Cancer Models","volume":"6","author":"Meraz","year":"2018","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.canlet.2026.218803_bib96","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-005769","article-title":"Activated NK cells reprogram MDSCs via NKG2D-NKG2DL and IFN-\u03b3 to modulate antitumor T-cell response after cryo-thermal therapy","volume":"10","author":"Peng","year":"2022","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.canlet.2026.218803_bib97","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1038\/s41416-025-03065-7","article-title":"CD49a(+) NK cells promote esophageal cancer development by inducing MDSCs infiltration via GM-CSF","volume":"133","author":"Cui","year":"2025","journal-title":"Br J Cancer"},{"key":"10.1016\/j.canlet.2026.218803_bib98","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1189\/jlb.3A0414-210R","article-title":"Cross-talk among myeloid-derived suppressor cells, macrophages, and tumor cells impacts the inflammatory milieu of solid tumors","volume":"96","author":"Beury","year":"2014","journal-title":"J Leukoc Biol"},{"key":"10.1016\/j.canlet.2026.218803_bib99","doi-asserted-by":"crossref","first-page":"156","DOI":"10.3109\/00365521.2010.516450","article-title":"Up-regulated myeloid-derived suppressor cell contributes to hepatocellular carcinoma development by impairing dendritic cell function","volume":"46","author":"Hu","year":"2011","journal-title":"Scand J Gastroenterol"},{"key":"10.1016\/j.canlet.2026.218803_bib100","doi-asserted-by":"crossref","first-page":"496","DOI":"10.3390\/vaccines13050496","article-title":"Harnessing Dendritic Cell Function in Hepatocellular Carcinoma: Advances in Immunotherapy and Therapeutic Strategies","volume":"13","author":"Ying","year":"2025","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.canlet.2026.218803_bib101","doi-asserted-by":"crossref","first-page":"3558","DOI":"10.3390\/cancers12123558","article-title":"Immune Regulation by Dendritic Cell Extracellular Vesicles in Cancer Immunotherapy and Vaccines","volume":"12","author":"Fern\u00e1ndez-Delgado","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.canlet.2026.218803_bib102","article-title":"VISTA promotes the metabolism and differentiation of myeloid-derived suppressor cells by STAT3 and polyamine-dependent mechanisms","volume":"43","author":"Zhang","year":"2024","journal-title":"Cell Rep"},{"key":"10.1016\/j.canlet.2026.218803_bib103","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1038\/s41401-025-01663-y","article-title":"TNFSF15 alleviates myeloid-derived suppressor cell-mediated cancer immunosuppression in mice","volume":"47","author":"Zhu","year":"2026","journal-title":"Acta Pharmacol Sin"},{"key":"10.1016\/j.canlet.2026.218803_bib104","doi-asserted-by":"crossref","first-page":"3295","DOI":"10.1021\/acsnano.3c10037","article-title":"Tumor-Microenvironment-Activatable Nanoparticle Mediating Immunogene Therapy and M2 Macrophage-Targeted Inhibitor for Synergistic Cancer Immunotherapy","volume":"18","author":"Hu","year":"2024","journal-title":"ACS Nano"},{"key":"10.1016\/j.canlet.2026.218803_bib105","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.1050484","article-title":"The effects of dendritic cell-based vaccines in the tumor microenvironment: Impact on myeloid-derived suppressor cells","volume":"13","author":"S\u00e1nchez-Le\u00f3n","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.canlet.2026.218803_bib106","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1038\/s41418-025-01496-6","article-title":"Targeting the poliovirus receptor to activate T cells and induce myeloid-derived suppressor cells to differentiate to pro-inflammatory macrophages via the IFN-\u03b3-p-STAT1-IRF8 axis in cancer therapy","volume":"32","author":"Feng","year":"2025","journal-title":"Cell Death Differ"},{"key":"10.1016\/j.canlet.2026.218803_bib107","doi-asserted-by":"crossref","first-page":"2413","DOI":"10.1038\/s41388-025-03425-w","article-title":"USP14-IMP2-CXCL2 axis in tumor-associated macrophages facilitates resistance to anti-PD-1 therapy in gastric cancer by recruiting myeloid-derived suppressor cells","volume":"44","author":"You","year":"2025","journal-title":"Oncogene"},{"key":"10.1016\/j.canlet.2026.218803_bib108","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/s13045-022-01248-w","article-title":"Solamargine induces hepatocellular carcinoma cell apoptosis and autophagy via inhibiting LIF\/miR-192-5p\/CYR61\/Akt signaling pathways and eliciting immunostimulatory tumor microenvironment","volume":"15","author":"Yin","year":"2022","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.canlet.2026.218803_bib109","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1186\/s12951-024-02417-4","article-title":"Biomimetic MDSCs membrane coated black phosphorus nanosheets system for photothermal therapy\/photodynamic therapy synergized chemotherapy of cancer","volume":"22","author":"Lan","year":"2024","journal-title":"J Nanobiotechnology"},{"key":"10.1016\/j.canlet.2026.218803_bib110","doi-asserted-by":"crossref","DOI":"10.1002\/smll.202309038","article-title":"ZIF-8-Encapsulated Pexidartinib Delivery via Targeted Peptide-Modified M1 Macrophages Attenuates MDSC-Mediated Immunosuppression in Osteosarcoma","volume":"20","author":"Dong","year":"2024","journal-title":"Small"},{"key":"10.1016\/j.canlet.2026.218803_bib111","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1186\/s13046-024-03138-0","article-title":"Tumor-derived GLI1 promotes remodeling of the immune tumor microenvironment in melanoma","volume":"43","author":"Giammona","year":"2024","journal-title":"J Exp Clin Cancer Res"},{"key":"10.1016\/j.canlet.2026.218803_bib112","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbrc.2024.151230","article-title":"IGF2-IGF1R signaling inhibition delays the growth of IGF2-high colorectal cancer by modulating MDSCs","volume":"746","author":"Zhu","year":"2025","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.canlet.2026.218803_bib113","doi-asserted-by":"crossref","DOI":"10.1016\/j.neo.2023.100920","article-title":"PI3K-CCL2-CCR2-MDSCs axis: A potential pathway for tumor Clostridia-promoted CD 8(+) T lymphocyte infiltration in bile tract cancers","volume":"43","author":"Ma","year":"2023","journal-title":"Neoplasia"},{"key":"10.1016\/j.canlet.2026.218803_bib114","doi-asserted-by":"crossref","first-page":"3174","DOI":"10.1002\/hep.32062","article-title":"IL-1\u03b2-Induced Elevation of Solute Carrier Family 7 Member 11 Promotes Hepatocellular Carcinoma Metastasis Through Up-regulating Programmed Death Ligand 1 and Colony-Stimulating Factor 1","volume":"74","author":"He","year":"2021","journal-title":"Hepatology"},{"key":"10.1016\/j.canlet.2026.218803_bib115","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1186\/s12967-025-06205-y","article-title":"RBM15 recruits myeloid-derived suppressor cells via the m6A-IGF2BP3\/CBR3-AS1\/miR-409-3p\/CXCL1 axis, facilitating radioresistance in non-small-cell lung cancer","volume":"23","author":"Hu","year":"2025","journal-title":"J Transl Med"},{"key":"10.1016\/j.canlet.2026.218803_bib116","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijbiomac.2025.143683","article-title":"Galectin-3 suppresses CD8(+) T cells function via myeloid-derived suppressor cells recruitment in cervical cancer","volume":"311","author":"Mai","year":"2025","journal-title":"Int J Biol Macromol"},{"key":"10.1016\/j.canlet.2026.218803_bib117","doi-asserted-by":"crossref","first-page":"4232","DOI":"10.7150\/thno.49819","article-title":"SPTBN1 inhibits inflammatory responses and hepatocarcinogenesis via the stabilization of SOCS1 and downregulation of p65 in hepatocellular carcinoma","volume":"11","author":"Lin","year":"2021","journal-title":"Theranostics"},{"key":"10.1016\/j.canlet.2026.218803_bib118","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1038\/s41590-024-02068-5","article-title":"The lactate receptor HCAR1 drives the recruitment of immunosuppressive PMN-MDSCs in colorectal cancer","volume":"26","author":"He","year":"2025","journal-title":"Nat Immunol"},{"key":"10.1016\/j.canlet.2026.218803_bib119","doi-asserted-by":"crossref","first-page":"3435","DOI":"10.1158\/0008-5472.CAN-24-3748","article-title":"Prostate Cancer Cells Secrete PD-1 in Exosomes to Enhance Myeloid-Derived Suppressor Cell Activity and Promote Tumor Immune Evasion","volume":"85","author":"Zhang","year":"2025","journal-title":"Cancer Res"},{"key":"10.1016\/j.canlet.2026.218803_bib120","doi-asserted-by":"crossref","first-page":"3156","DOI":"10.1158\/0008-5472.CAN-15-2528","article-title":"Myeloid-Derived Suppressor Cells Endow Stem-like Qualities to Breast Cancer Cells through IL6\/STAT3 and NO\/NOTCH Cross-talk Signaling","volume":"76","author":"Peng","year":"2016","journal-title":"Cancer Res"},{"key":"10.1016\/j.canlet.2026.218803_bib121","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/j.immuni.2013.08.025","article-title":"Myeloid-derived suppressor cells enhance stemness of cancer cells by inducing microRNA101 and suppressing the corepressor CtBP2","volume":"39","author":"Cui","year":"2013","journal-title":"Immunity"},{"key":"10.1016\/j.canlet.2026.218803_bib122","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1007\/s00262-014-1527-x","article-title":"Tumor-induced STAT3 activation in monocytic myeloid-derived suppressor cells enhances stemness and mesenchymal properties in human pancreatic cancer","volume":"63","author":"Panni","year":"2014","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.canlet.2026.218803_bib123","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pbio.1001162","article-title":"Mesenchymal transition and dissemination of cancer cells is driven by myeloid-derived suppressor cells infiltrating the primary tumor","volume":"9","author":"Toh","year":"2011","journal-title":"PLoS Biol"},{"key":"10.1016\/j.canlet.2026.218803_bib124","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms14979","article-title":"Monocytic and granulocytic myeloid derived suppressor cells differentially regulate spatiotemporal tumour plasticity during metastatic cascade","volume":"8","author":"Ouzounova","year":"2017","journal-title":"Nat Commun"},{"key":"10.1016\/j.canlet.2026.218803_bib125","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1038\/s41388-020-01605-4","article-title":"Myeloid-derived suppressor cells promote lung cancer metastasis by CCL11 to activate ERK and AKT signaling and induce epithelial-mesenchymal transition in tumor cells","volume":"40","author":"Lin","year":"2021","journal-title":"Oncogene"},{"key":"10.1016\/j.canlet.2026.218803_bib126","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1158\/0008-5472.CAN-11-2905","article-title":"Myeloid progenitor cells in the premetastatic lung promote metastases by inducing mesenchymal to epithelial transition","volume":"72","author":"Gao","year":"2012","journal-title":"Cancer Res"},{"key":"10.1016\/j.canlet.2026.218803_bib127","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1002\/ijc.30538","article-title":"Recruited monocytic myeloid-derived suppressor cells promote the arrest of tumor cells in the premetastatic niche through an IL-1\u03b2-mediated increase in E-selectin expression","volume":"140","author":"Shi","year":"2017","journal-title":"Int J Cancer"},{"key":"10.1016\/j.canlet.2026.218803_bib128","doi-asserted-by":"crossref","first-page":"5283","DOI":"10.1158\/0008-5472.CAN-15-2282-T","article-title":"CCL9 Induced by TGF\u03b2 Signaling in Myeloid Cells Enhances Tumor Cell Survival in the Premetastatic Organ","volume":"75","author":"Yan","year":"2015","journal-title":"Cancer Res"},{"key":"10.1016\/j.canlet.2026.218803_bib129","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1146\/annurev-med-051013-052304","article-title":"Regulation of tumor metastasis by myeloid-derived suppressor cells","volume":"66","author":"Condamine","year":"2015","journal-title":"Annu Rev Med"},{"key":"10.1016\/j.canlet.2026.218803_bib130","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbcan.2021.188564","article-title":"Epithelial-mesenchymal transition: When tumor cells meet myeloid-derived suppressor cells","volume":"1876","author":"Cai","year":"2021","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"10.1016\/j.canlet.2026.218803_bib131","doi-asserted-by":"crossref","first-page":"4015","DOI":"10.1172\/JCI45862","article-title":"Tumor-infiltrating myeloid cells induce tumor cell resistance to cytotoxic T cells in mice","volume":"121","author":"Lu","year":"2011","journal-title":"J Clin Invest"},{"key":"10.1016\/j.canlet.2026.218803_bib132","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1038\/onc.2016.229","article-title":"Exosomes miR-126a released from MDSC induced by DOX treatment promotes lung metastasis","volume":"36","author":"Deng","year":"2017","journal-title":"Oncogene"},{"key":"10.1016\/j.canlet.2026.218803_bib133","doi-asserted-by":"crossref","first-page":"2258","DOI":"10.2174\/0113816128256397230920093628","article-title":"CD39+MDSC Facilitates Cisplatin Resistance of Ovarian Cancer Cells by Affecting Adenosine Synthesis","volume":"29","author":"Ma","year":"2023","journal-title":"Curr Pharm Des"},{"key":"10.1016\/j.canlet.2026.218803_bib134","article-title":"Cancer-Associated Fibroblast-Induced Remodeling of Tumor Microenvironment in Recurrent Bladder Cancer","volume":"10","author":"Liang","year":"2023","journal-title":"Adv Sci (Weinh)"},{"key":"10.1016\/j.canlet.2026.218803_bib135","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.767939","article-title":"Exploiting the STAT3 Nexus in Cancer-Associated Fibroblasts to Improve Cancer Therapy","volume":"12","author":"Allam","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.canlet.2026.218803_bib136","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1002\/hep.32099","article-title":"CAFs shape myeloid-derived suppressor cells to promote stemness of intrahepatic cholangiocarcinoma through 5-lipoxygenase","volume":"75","author":"Lin","year":"2022","journal-title":"Hepatology"},{"key":"10.1016\/j.canlet.2026.218803_bib137","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0117908","article-title":"TGF\u03b2 signaling in myeloid cells regulates mammary carcinoma cell invasion through fibroblast interactions","volume":"10","author":"Shaw","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.canlet.2026.218803_bib138","doi-asserted-by":"crossref","first-page":"2472","DOI":"10.1158\/0008-5472.CAN-21-3896","article-title":"Claudin-12 Deficiency Inhibits Tumor Growth by Impairing Transendothelial Migration of Myeloid-Derived Suppressor Cells","volume":"82","author":"Cao","year":"2022","journal-title":"Cancer Res"},{"key":"10.1016\/j.canlet.2026.218803_bib139","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1016\/j.jhep.2024.09.044","article-title":"CXCL12(+) tumor-associated endothelial cells promote immune resistance in hepatocellular carcinoma","volume":"82","author":"Lu","year":"2025","journal-title":"J Hepatol"},{"key":"10.1016\/j.canlet.2026.218803_bib140","doi-asserted-by":"crossref","first-page":"4196","DOI":"10.1158\/0008-5472.CAN-18-3657","article-title":"Activation of the VEGFC\/VEGFR3 Pathway Induces Tumor Immune Escape in Colorectal Cancer","volume":"79","author":"Tacconi","year":"2019","journal-title":"Cancer Res"},{"key":"10.1016\/j.canlet.2026.218803_bib141","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djv209","article-title":"Role of Tumor Pericytes in the Recruitment of Myeloid-Derived Suppressor Cells","volume":"107","author":"Hong","year":"2015","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.canlet.2026.218803_bib142","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1002\/oby.23108","article-title":"Obesity-Associated Myeloid Immunosuppressive Cells, Key Players in Cancer Risk and Response to Immunotherapy","volume":"29","author":"Sanchez-Pino","year":"2021","journal-title":"Obesity (Silver Spring)"},{"key":"10.1016\/j.canlet.2026.218803_bib143","article-title":"Targeting lipid metabolism reprogramming of immunocytes in response to the tumor microenvironment stressor: A potential approach for tumor therapy","volume":"13","author":"Zhang","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.canlet.2026.218803_bib144","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1158\/2326-6066.CIR-15-0036","article-title":"Inhibition of Fatty Acid Oxidation Modulates Immunosuppressive Functions of Myeloid-Derived Suppressor Cells and Enhances Cancer Therapies","volume":"3","author":"Hossain","year":"2015","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.canlet.2026.218803_bib145","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2017.1344804","article-title":"Exogenous lipid uptake induces metabolic and functional reprogramming of tumor-associated myeloid-derived suppressor cells","volume":"6","author":"Al-Khami","year":"2017","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.canlet.2026.218803_bib146","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1111\/imcb.12360","article-title":"Adipose-resident myeloid-derived suppressor cells modulate immune cell homeostasis in healthy mice","volume":"98","author":"Stivers","year":"2020","journal-title":"Immunol Cell Biol"},{"key":"10.1016\/j.canlet.2026.218803_bib147","doi-asserted-by":"crossref","first-page":"497","DOI":"10.4049\/jimmunol.2200064","article-title":"Activin A-Expressing Polymorphonuclear Myeloid-Derived Suppressor Cells Infiltrate Skeletal and Cardiac Muscle and Promote Cancer Cachexia","volume":"211","author":"Dzierlega","year":"2023","journal-title":"J Immunol"},{"key":"10.1016\/j.canlet.2026.218803_bib148","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbrc.2024.150408","article-title":"Myeloid-derived suppressor cells in the tumor microenvironment reduce uncoupling protein 1 expression to boost immunosuppressive activity","volume":"732","author":"Zhao","year":"2024","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.canlet.2026.218803_bib149","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2023.110413","article-title":"All-trans-retinoic acid inhibits hepatocellular carcinoma progression by targeting myeloid-derived suppressor cells and inhibiting angiogenesis","volume":"121","author":"Li","year":"2023","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.canlet.2026.218803_bib150","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1007\/s10238-022-00860-x","article-title":"The immunomodulatory role of all-trans retinoic acid in tumor microenvironment","volume":"23","author":"Bi","year":"2023","journal-title":"Clin Exp Med"},{"key":"10.1016\/j.canlet.2026.218803_bib151","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.intimp.2018.08.007","article-title":"Targeting myeloid-derived suppressor cells using all-trans retinoic acid in melanoma patients treated with Ipilimumab","volume":"63","author":"Tobin","year":"2018","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.canlet.2026.218803_bib152","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1158\/1078-0432.CCR-22-2495","article-title":"Targeting MDSC Differentiation Using ATRA: A Phase I\/II Clinical Trial Combining Pembrolizumab and All-Trans Retinoic Acid for Metastatic Melanoma","volume":"29","author":"Tobin","year":"2023","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.canlet.2026.218803_bib153","doi-asserted-by":"crossref","first-page":"9619","DOI":"10.1038\/s41598-022-13855-1","article-title":"Inhibition of myeloid-derived suppressive cell function with all-trans retinoic acid enhanced anti-PD-L1 efficacy in cervical cancer","volume":"12","author":"Liang","year":"2022","journal-title":"Sci Rep"},{"key":"10.1016\/j.canlet.2026.218803_bib154","doi-asserted-by":"crossref","first-page":"4715","DOI":"10.1158\/0008-5472.CAN-19-0053","article-title":"Melanoma Extracellular Vesicles Generate Immunosuppressive Myeloid Cells by Upregulating PD-L1 via TLR4 Signaling","volume":"79","author":"Fleming","year":"2019","journal-title":"Cancer Res"},{"key":"10.1016\/j.canlet.2026.218803_bib155","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-005551","article-title":"HSP90\u03b1 induces immunosuppressive myeloid cells in melanoma via TLR4 signaling","volume":"10","author":"Arkhypov","year":"2022","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.canlet.2026.218803_bib156","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.molimm.2019.06.006","article-title":"TLR1\/TLR2 signaling blocks the suppression of monocytic myeloid-derived suppressor cell by promoting its differentiation into M1-type macrophage","volume":"112","author":"Deng","year":"2019","journal-title":"Mol Immunol"},{"key":"10.1016\/j.canlet.2026.218803_bib157","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.canlet.2019.10.020","article-title":"TLR 7\/8 agonist reverses oxaliplatin resistance in colorectal cancer via directing the myeloid-derived suppressor cells to tumoricidal M1-macrophages","volume":"469","author":"Liu","year":"2020","journal-title":"Cancer Lett"},{"key":"10.1016\/j.canlet.2026.218803_bib158","doi-asserted-by":"crossref","first-page":"2388","DOI":"10.3389\/fimmu.2019.02388","article-title":"The Role of TLRs in Anti-cancer Immunity and Tumor Rejection","volume":"10","author":"Urban-Wojciuk","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.canlet.2026.218803_bib159","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1186\/s40425-019-0734-6","article-title":"Immunosuppression by monocytic myeloid-derived suppressor cells in patients with pancreatic ductal carcinoma is orchestrated by STAT3","volume":"7","author":"Trovato","year":"2019","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.canlet.2026.218803_bib160","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1186\/s40425-018-0436-5","article-title":"STAT3 antisense oligonucleotide AZD9150 in a subset of patients with heavily pretreated lymphoma: results of a phase 1b trial","volume":"6","author":"Reilley","year":"2018","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.canlet.2026.218803_bib161","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2023.109839","article-title":"Dioscin modulates macrophages polarization and MDSCs differentiation to inhibit tumorigenesis of colitis-associated colorectal cancer","volume":"117","author":"Xun","year":"2023","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.canlet.2026.218803_bib162","article-title":"Ganoderma lucidum polysaccharide (GLP) enhances antitumor immune response by regulating differentiation and inhibition of MDSCs via a CARD9-NF-\u03baB-IDO pathway","volume":"40","author":"Wang","year":"2020","journal-title":"Biosci Rep"},{"key":"10.1016\/j.canlet.2026.218803_bib163","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2022.108964","article-title":"Role of sanguinarine in regulating immunosuppression in a Lewis lung cancer mouse model","volume":"110","author":"Li","year":"2022","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.canlet.2026.218803_bib164","doi-asserted-by":"crossref","first-page":"14988","DOI":"10.1002\/cam4.6135","article-title":"Randomized, Phase II study of pemetrexed plus bevacizumab versus pemetrexed alone after treatment with cisplatin, pemetrexed, and bevacizumab in advanced non-squamous, non-small cell lung cancer: TORG (thoracic oncology research group) 1321","volume":"12","author":"Kasai","year":"2023","journal-title":"Cancer Med"},{"key":"10.1016\/j.canlet.2026.218803_bib165","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1016\/j.jtho.2018.03.032","article-title":"Bevacizumab Reduces S100A9-Positive MDSCs Linked to Intracranial Control in Patients with EGFR-Mutant Lung Adenocarcinoma","volume":"13","author":"Feng","year":"2018","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.canlet.2026.218803_bib166","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1073\/pnas.1910856117","article-title":"CCR2 inhibition reduces tumor myeloid cells and unmasks a checkpoint inhibitor effect to slow progression of resistant murine gliomas","volume":"117","author":"Flores-Toro","year":"2020","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.canlet.2026.218803_bib167","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1111\/cas.14306","article-title":"Phase I dose-escalation trial to repurpose propagermanium, an oral CCL2 inhibitor, in patients with breast cancer","volume":"111","author":"Masuda","year":"2020","journal-title":"Cancer Sci"},{"key":"10.1016\/j.canlet.2026.218803_bib168","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2022.215598","article-title":"PMN-MDSCs accumulation induced by CXCL1 promotes CD8(+) T cells exhaustion in gastric cancer","volume":"532","author":"Zhou","year":"2022","journal-title":"Cancer Lett"},{"key":"10.1016\/j.canlet.2026.218803_bib169","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1038\/s41591-020-0880-x","article-title":"BL-8040, a CXCR4 antagonist, in combination with pembrolizumab and chemotherapy for pancreatic cancer: the COMBAT trial","volume":"26","author":"Bockorny","year":"2020","journal-title":"Nat Med"},{"key":"10.1016\/j.canlet.2026.218803_bib170","doi-asserted-by":"crossref","first-page":"3193","DOI":"10.1016\/j.ymthe.2023.09.010","article-title":"CXCR4-modified CAR-T cells suppresses MDSCs recruitment via STAT3\/NF-\u03baB\/SDF-1\u03b1 axis to enhance efficacy against pancreatic cancer","volume":"31","author":"Sun","year":"2023","journal-title":"Mol Ther"},{"key":"10.1016\/j.canlet.2026.218803_bib171","article-title":"IL-1\u03b2 Is an Androgen-Responsive Target in Macrophages for Immunotherapy of Prostate Cancer","volume":"10","author":"Wang","year":"2023","journal-title":"Adv Sci (Weinh)"},{"key":"10.1016\/j.canlet.2026.218803_bib172","article-title":"NLRP3\/IL-1\u03b2 induced myeloid-derived suppressor cells recruitment and PD-L1 upregulation promotes oxaliplatin resistance of hepatocellular carcinoma","volume":"4","author":"Liu","year":"2020","journal-title":"MedComm"},{"key":"10.1016\/j.canlet.2026.218803_bib173","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.157788","article-title":"Targeting IL-1\u03b2 as an immunopreventive and therapeutic modality for K-ras-mutant lung cancer","volume":"7","author":"Yuan","year":"2022","journal-title":"JCI Insight"},{"key":"10.1016\/j.canlet.2026.218803_bib174","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1007\/s10637-022-01218-6","article-title":"Blockade of Myd88 signaling by a novel MyD88 inhibitor prevents colitis-associated colorectal cancer development by impairing myeloid-derived suppressor cells","volume":"40","author":"Wang","year":"2022","journal-title":"Invest New Drugs"},{"key":"10.1016\/j.canlet.2026.218803_bib175","doi-asserted-by":"crossref","DOI":"10.1016\/j.jep.2023.116491","article-title":"The Tian-Men-Dong decoction suppresses the tumour-infiltrating G-MDSCs via IL-1\u03b2-mediated signalling in lung cancer","volume":"313","author":"Su","year":"2023","journal-title":"J Ethnopharmacol"},{"key":"10.1016\/j.canlet.2026.218803_bib176","article-title":"Antidiabetic DPP-4 Inhibitors Reprogram Tumor Microenvironment That Facilitates Murine Breast Cancer Metastasis Through Interaction With Cancer Cells via a ROS-NF-\u043aB-NLRP3 Axis","volume":"11","author":"Li","year":"2021","journal-title":"Front Oncol"},{"key":"10.1016\/j.canlet.2026.218803_bib177","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-005319","article-title":"Tasquinimod suppresses tumor cell growth and bone resorption by targeting immunosuppressive myeloid cells and inhibiting c-MYC expression in multiple myeloma","volume":"11","author":"Fan","year":"2023","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.canlet.2026.218803_bib178","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2023.110869","article-title":"TMPRSS11D\/ALR-mediated ER stress regulates the function of myeloid-derived suppressor cells in the cervical cancer microenvironment","volume":"124","author":"Feng","year":"2023","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.canlet.2026.218803_bib179","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1021\/acsptsci.3c00014","article-title":"Fluorescent Detection of Peroxynitrite Produced by Myeloid-Derived Suppressor Cells in Cancer and Inhibition by Dasatinib","volume":"6","author":"Carlson","year":"2023","journal-title":"ACS Pharmacol Transl Sci"},{"key":"10.1016\/j.canlet.2026.218803_bib180","doi-asserted-by":"crossref","DOI":"10.4028\/b-wjQRP6","article-title":"A NRF2 Regulated and the Immunosuppressive Microenvironment Reversed Nanoplatform for Cholangiocarcinoma Photodynamic-Gas Therapy","volume":"11","author":"Wang","year":"2024","journal-title":"Adv Sci (Weinh)"},{"key":"10.1016\/j.canlet.2026.218803_bib181","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1158\/1078-0432.CCR-14-1716","article-title":"Tadalafil augments tumor specific immunity in patients with head and neck squamous cell carcinoma","volume":"21","author":"Califano","year":"2015","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.canlet.2026.218803_bib182","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.3389\/fimmu.2019.01206","article-title":"The Reversal of Immune Exclusion Mediated by Tadalafil and an Anti-tumor Vaccine Also Induces PDL1 Upregulation in Recurrent Head and Neck Squamous Cell Carcinoma: Interim Analysis of a Phase I Clinical Trial","volume":"10","author":"Weed","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.canlet.2026.218803_bib183","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1158\/2326-6066.CIR-13-0213","article-title":"Targeting immune suppression with PDE5 inhibition in end-stage multiple myeloma","volume":"2","author":"Noonan","year":"2014","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.canlet.2026.218803_bib184","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2018.1431082","article-title":"Phosphodiesterase-5 inhibition reduces postoperative metastatic disease by targeting surgery-induced myeloid derived suppressor cell-dependent inhibition of Natural Killer cell cytotoxicity","volume":"7","author":"Tai","year":"2018","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.canlet.2026.218803_bib185","doi-asserted-by":"crossref","DOI":"10.1016\/j.prostaglandins.2019.106338","article-title":"Prostaglandin E2 as a potent therapeutic target for treatment of colon cancer","volume":"144","author":"Karpisheh","year":"2019","journal-title":"Prostaglandins Other Lipid Mediat"},{"key":"10.1016\/j.canlet.2026.218803_bib186","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1186\/1471-2407-10-464","article-title":"COX-2 inhibition improves immunotherapy and is associated with decreased numbers of myeloid-derived suppressor cells in mesothelioma. Celecoxib influences MDSC function","volume":"10","author":"Veltman","year":"2010","journal-title":"BMC Cancer"},{"key":"10.1016\/j.canlet.2026.218803_bib187","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1007\/s00262-014-1561-8","article-title":"Combination of an agonistic anti-CD40 monoclonal antibody and the COX-2 inhibitor celecoxib induces anti-glioma effects by promotion of type-1 immunity in myeloid cells and T-cells","volume":"63","author":"Kosaka","year":"2014","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.canlet.2026.218803_bib188","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1158\/1078-0432.CCR-21-0299","article-title":"Single-Cell Analysis Reveals EP4 as a Target for Restoring T-Cell Infiltration and Sensitizing Prostate Cancer to Immunotherapy","volume":"28","author":"Peng","year":"2022","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.canlet.2026.218803_bib189","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1158\/0008-5472.CAN-24-1130","article-title":"GLI2 Facilitates Tumor Immune Evasion and Immunotherapeutic Resistance by Coordinating WNT and Prostaglandin Signaling","volume":"85","author":"DeVito","year":"2025","journal-title":"Cancer Res"},{"key":"10.1016\/j.canlet.2026.218803_bib190","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2019-000222","article-title":"First-in-human phase I study of immunomodulatory E7046, an antagonist of PGE(2)-receptor E-type 4 (EP4), in patients with advanced cancers","volume":"8","author":"Hong","year":"2020","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.canlet.2026.218803_bib191","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.690207","article-title":"Regulatory Effects of Histone Deacetylase Inhibitors on Myeloid-Derived Suppressor Cells","volume":"12","author":"Cui","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.canlet.2026.218803_bib192","doi-asserted-by":"crossref","first-page":"5187","DOI":"10.1158\/1078-0432.CCR-17-0741","article-title":"Entinostat Neutralizes Myeloid-Derived Suppressor Cells and Enhances the Antitumor Effect of PD-1 Inhibition in Murine Models of Lung and Renal Cell Carcinoma","volume":"23","author":"Orillion","year":"2017","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.canlet.2026.218803_bib193","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.jphs.2018.06.014","article-title":"Valproic acid attenuates immunosuppressive function of myeloid-derived suppressor cells","volume":"137","author":"Xie","year":"2018","journal-title":"J Pharmacol Sci"},{"key":"10.1016\/j.canlet.2026.218803_bib194","doi-asserted-by":"crossref","DOI":"10.1016\/j.cellimm.2021.104286","article-title":"Regulation of ROS in myeloid-derived suppressor cells through targeting fatty acid transport protein 2 enhanced anti-PD-L1 tumor immunotherapy","volume":"362","author":"Adeshakin","year":"2021","journal-title":"Cell Immunol"},{"key":"10.1016\/j.canlet.2026.218803_bib195","doi-asserted-by":"crossref","DOI":"10.1016\/j.phymed.2023.155171","article-title":"Shenqi Fuzheng injection modulates tumor fatty acid metabolism to downregulate MDSCs infiltration, enhancing PD-L1 antibody inhibition of intracranial growth in Melanoma","volume":"122","author":"Ma","year":"2024","journal-title":"Phytomedicine"},{"key":"10.1016\/j.canlet.2026.218803_bib196","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1038\/s41423-025-01260-3","article-title":"GLP1 alleviates oleic acid-propelled lipocalin-2 generation by tumor-infiltrating CD8(+) T cells to reduce polymorphonuclear MDSC recruitment and enhances viral immunotherapy in pancreatic cancer","volume":"22","author":"Wu","year":"2025","journal-title":"Cell Mol Immunol"},{"key":"10.1016\/j.canlet.2026.218803_bib197","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s12943-025-02238-5","article-title":"Sorafenib enhanced the function of myeloid-derived suppressor cells in hepatocellular carcinoma by facilitating PPAR\u03b1-mediated fatty acid oxidation","volume":"24","author":"Li","year":"2025","journal-title":"Mol Cancer"},{"key":"10.1016\/j.canlet.2026.218803_bib198","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1158\/1535-7163.MCT-22-0282","article-title":"Sirpiglenastat (DRP-104) Induces Antitumor Efficacy through Direct, Broad Antagonism of Glutamine Metabolism and Stimulation of the Innate and Adaptive Immune Systems","volume":"21","author":"Yokoyama","year":"2022","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.canlet.2026.218803_bib199","doi-asserted-by":"crossref","DOI":"10.1016\/j.cellimm.2021.104384","article-title":"STING agonist and IDO inhibitor combination therapy inhibits tumor progression in murine models of colorectal cancer","volume":"366","author":"Shi","year":"2021","journal-title":"Cell Immunol"},{"key":"10.1016\/j.canlet.2026.218803_bib200","article-title":"Trial watch: IDO inhibitors in cancer therapy","volume":"9","author":"Le Naour","year":"2020","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.canlet.2026.218803_bib201","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s00281-018-0702-0","article-title":"Inhibiting IDO pathways to treat cancer: lessons from the ECHO-301 trial and beyond","volume":"41","author":"Muller","year":"2019","journal-title":"Semin Immunopathol"},{"key":"10.1016\/j.canlet.2026.218803_bib202","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1007\/s00262-014-1553-8","article-title":"Extracellular adenosine metabolism in immune cells in melanoma","volume":"63","author":"Umansky","year":"2014","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.canlet.2026.218803_bib203","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/s12943-023-01733-x","article-title":"CD39\/CD73\/A2AR pathway and cancer immunotherapy","volume":"22","author":"Xia","year":"2023","journal-title":"Mol Cancer"},{"key":"10.1016\/j.canlet.2026.218803_bib204","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2025.114907","article-title":"Eleutheroside A inhibits PI3K\/AKT1\/mTOR-mediated glycolysis in MDSCs to alleviate their immunosuppressive function in gastric cancer","volume":"159","author":"Jiang","year":"2025","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.canlet.2026.218803_bib205","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1111\/cas.15620","article-title":"S-1 eliminates MDSCs and enhances the efficacy of PD-1 blockade via regulation of tumor-derived Bv8 and S100A8 in thoracic tumor","volume":"114","author":"Nguyen","year":"2023","journal-title":"Cancer Sci"},{"key":"10.1016\/j.canlet.2026.218803_bib206","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2023.110129","article-title":"5-FU mediated depletion of myeloid suppressor cells enhances T-cell infiltration and anti-tumor response in immunotherapy-resistant lung tumor","volume":"120","author":"Mathew","year":"2023","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.canlet.2026.218803_bib207","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1158\/0008-5472.CAN-13-1545","article-title":"Doxorubicin eliminates myeloid-derived suppressor cells and enhances the efficacy of adoptive T-cell transfer in breast cancer","volume":"74","author":"Alizadeh","year":"2014","journal-title":"Cancer Res"},{"key":"10.1016\/j.canlet.2026.218803_bib208","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.biomaterials.2018.10.022","article-title":"Gemcitabine nanoparticles promote antitumor immunity against melanoma","volume":"189","author":"Zhang","year":"2019","journal-title":"Biomaterials"},{"key":"10.1016\/j.canlet.2026.218803_bib209","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.130748","article-title":"Metronomic capecitabine as an immune modulator in glioblastoma patients reduces myeloid-derived suppressor cells","volume":"4","author":"Peereboom","year":"2019","journal-title":"JCI Insight"},{"key":"10.1016\/j.canlet.2026.218803_bib210","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1158\/2326-6066.CIR-23-1073","article-title":"Blockade of IL1\u03b2 and PD1 with Combination Chemotherapy Reduces Systemic Myeloid Suppression in Metastatic Pancreatic Cancer with Heterogeneous Effects in the Tumor","volume":"12","author":"Oberstein","year":"2024","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.canlet.2026.218803_bib211","doi-asserted-by":"crossref","DOI":"10.1016\/j.cellimm.2020.104274","article-title":"Potential therapeutic effect of low-dose paclitaxel in melanoma patients resistant to immune checkpoint blockade: A pilot study","volume":"360","author":"Gebhardt","year":"2021","journal-title":"Cell Immunol"},{"key":"10.1016\/j.canlet.2026.218803_bib212","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.molimm.2021.06.012","article-title":"Intra-arterial infusion chemotherapy utilizing cisplatin inhibits bladder cancer by decreasing the fibrocytic myeloid-derived suppressor cells in an m6A-dependent manner","volume":"137","author":"Mu","year":"2021","journal-title":"Mol Immunol"},{"key":"10.1016\/j.canlet.2026.218803_bib213","first-page":"999","article-title":"Different immunological effects of the molecular targeted agents sunitinib, everolimus and temsirolimus in patients with renal cell carcinoma","volume":"56","author":"Kobayashi","year":"2020","journal-title":"Int J Oncol"},{"key":"10.1016\/j.canlet.2026.218803_bib214","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.2217\/fon-2019-0725","article-title":"Sunitinib inhibits PD-L1 expression in osteosarcoma by targeting STAT3 and remodels the immune system in tumor-bearing mice","volume":"16","author":"Duan","year":"2020","journal-title":"Future Oncol"},{"key":"10.1016\/j.canlet.2026.218803_bib215","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2023.110243","article-title":"Sunitinib attenuates reactive MDSCs enhancing anti-tumor immunity in HNSCC","volume":"119","author":"Liu","year":"2023","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.canlet.2026.218803_bib216","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1097\/CJI.0000000000000301","article-title":"CAIX-specific CAR-T Cells and Sunitinib Show Synergistic Effects Against Metastatic Renal Cancer Models","volume":"43","author":"Li","year":"2020","journal-title":"J Immunother"},{"key":"10.1016\/j.canlet.2026.218803_bib217","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2022.109470","article-title":"Myeloid-derived suppressor cells (MDSCs) depletion by cabozantinib improves the efficacy of anti-HER2 antibody-based immunotherapy in a 4T1-HER2 murine breast cancer model","volume":"113","author":"Khaki Bakhtiarvand","year":"2022","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.canlet.2026.218803_bib218","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1038\/s41388-018-0449-z","article-title":"STAT3 inhibition induces Bax-dependent apoptosis in liver tumor myeloid-derived suppressor cells","volume":"38","author":"Guha","year":"2019","journal-title":"Oncogene"},{"key":"10.1016\/j.canlet.2026.218803_bib219","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2022.2152248","article-title":"Selective depletion of polymorphonuclear myeloid derived suppressor cells in tumor beds with near infrared photoimmunotherapy enhances host immune response","volume":"11","author":"Kato","year":"2022","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.canlet.2026.218803_bib220","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.1007\/s00262-020-02615-7","article-title":"NKG2D-Fc fusion protein promotes antitumor immunity through the depletion of immunosuppressive cells","volume":"69","author":"Feng","year":"2020","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.canlet.2026.218803_bib221","doi-asserted-by":"crossref","first-page":"55804","DOI":"10.18632\/oncotarget.18437","article-title":"Resistance to CTLA-4 checkpoint inhibition reversed through selective elimination of granulocytic myeloid cells","volume":"8","author":"Clavijo","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.canlet.2026.218803_bib222","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2023.2247303","article-title":"Melanoma patients with immune-related adverse events after immune checkpoint inhibitors are characterized by a distinct immunological phenotype of circulating T cells and M-MDSCs","volume":"12","author":"Lepper","year":"2023","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.canlet.2026.218803_bib223","doi-asserted-by":"crossref","first-page":"11774","DOI":"10.1073\/pnas.1410626111","article-title":"Eradication of metastatic mouse cancers resistant to immune checkpoint blockade by suppression of myeloid-derived cells","volume":"111","author":"Kim","year":"2014","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.canlet.2026.218803_bib224","article-title":"KAT6A Acetylation of SMAD3 Regulates Myeloid-Derived Suppressor Cell Recruitment, Metastasis, and Immunotherapy in Triple-Negative Breast Cancer","volume":"8","author":"Yu","year":"2021","journal-title":"Adv Sci (Weinh)"},{"key":"10.1016\/j.canlet.2026.218803_bib225","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aba9772","article-title":"Reactivation of the tumor suppressor PTEN by mRNA nanoparticles enhances antitumor immunity in preclinical models","volume":"13","author":"Lin","year":"2021","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.canlet.2026.218803_bib226","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.2147\/IJN.S492734","article-title":"LBP-CD155 Liposome Nanovaccine Efficiently Resist Colorectal Cancer and Enhance ICB Therapy","volume":"20","author":"Yan","year":"2025","journal-title":"Int J Nanomedicine"},{"key":"10.1016\/j.canlet.2026.218803_bib227","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1186\/s13046-025-03396-6","article-title":"A novel pH-sensitive nanoparticles encapsulating anti-PD-1 antibody and MDK-siRNA overcome immune checkpoint blockade resistance in HCC via reshaping immunosuppressive TME","volume":"44","author":"Xu","year":"2025","journal-title":"J Exp Clin Cancer Res"},{"key":"10.1016\/j.canlet.2026.218803_bib228","doi-asserted-by":"crossref","first-page":"4114","DOI":"10.1038\/s41388-025-03567-x","article-title":"A novel FAP-targeting antibody-exatecan conjugate improves immune checkpoint blockade by reversing immunosuppressive microenvironment in pancreatic cancer","volume":"44","author":"Wei","year":"2025","journal-title":"Oncogene"},{"key":"10.1016\/j.canlet.2026.218803_bib229","doi-asserted-by":"crossref","first-page":"4981","DOI":"10.1016\/j.cell.2021.08.004","article-title":"The immunostimulatory RNA RN7SL1 enables CAR-T cells to enhance autonomous and endogenous immune function","volume":"184","author":"Johnson","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.canlet.2026.218803_bib230","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-006239","article-title":"IL15 modification enables CAR T cells to act as a dual targeting agent against tumor cells and myeloid-derived suppressor cells in GBM","volume":"11","author":"Zannikou","year":"2023","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.canlet.2026.218803_bib231","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1186\/s12967-023-04080-z","article-title":"FAP-targeted CAR-T suppresses MDSCs recruitment to improve the antitumor efficacy of claudin18.2-targeted CAR-T against pancreatic cancer","volume":"21","author":"Liu","year":"2023","journal-title":"J Transl Med"},{"key":"10.1016\/j.canlet.2026.218803_bib232","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1007\/s11523-017-0525-2","article-title":"A phase II multicentre, open-label, proof-of-concept study of tasquinimod in hepatocellular, ovarian, renal cell, and gastric cancers","volume":"12","author":"Escudier","year":"2017","journal-title":"Target Oncol"},{"key":"10.1016\/j.canlet.2026.218803_bib233","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1200\/JCO.2016.66.9697","article-title":"Randomized, double-blind, placebo-controlled phase III study of tasquinimod in men with metastatic castration-resistant prostate cancer","volume":"34","author":"Sternberg","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.canlet.2026.218803_bib234","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1007\/s10549-021-06367-5","article-title":"A randomized, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for metastatic triple-negative breast cancer (fRida)","volume":"190","author":"Goldstein","year":"2021","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.canlet.2026.218803_bib235","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/s10637-023-01410-2","article-title":"CXCR2 antagonist navarixin in combination with pembrolizumab in select advanced solid tumors: a phase 2 randomized trial","volume":"42","author":"Armstrong","year":"2024","journal-title":"Invest New Drugs"},{"key":"10.1016\/j.canlet.2026.218803_bib236","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1158\/1078-0432.CCR-14-1711","article-title":"Tadalafil reduces myeloid-derived suppressor cells and regulatory T cells and promotes tumor immunity in patients with head and neck squamous cell carcinoma","volume":"21","author":"Weed","year":"2015","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.canlet.2026.218803_bib237","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1016\/S1470-2045(19)30274-8","article-title":"Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301\/KEYNOTE-252): a phase 3, randomised, double-blind study","volume":"20","author":"Long","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.canlet.2026.218803_bib238","article-title":"Preclinical study and parallel phase II trial evaluating antisense STAT3 oligonucleotide and checkpoint blockade for advanced pancreatic, non-small cell lung cancer and mismatch repair-deficient colorectal cancer","volume":"3","author":"Tang","year":"2024","journal-title":"BMJ Oncol"},{"key":"10.1016\/j.canlet.2026.218803_bib239","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.169927","article-title":"Inhibition of Bruton's tyrosine kinase with PD-1 blockade modulates T cell activation in solid tumors","volume":"9","author":"Schwarz","year":"2024","journal-title":"JCI Insight"},{"key":"10.1016\/j.canlet.2026.218803_bib240","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1210\/clinem\/dgae512","article-title":"Cabozantinib Plus Ipilimumab\/Nivolumab in Patients With Previously Treated Advanced Differentiated Thyroid Cancer","volume":"110","author":"Konda","year":"2025","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.canlet.2026.218803_bib241","doi-asserted-by":"crossref","DOI":"10.1634\/theoncologist.2018-0652","article-title":"Modulation of Premetastatic Niche by the Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor Pazopanib in Localized High-Risk Prostate Cancer Followed by Radical Prostatectomy: A Phase II Randomized Trial","volume":"23","author":"Maughan","year":"2018","journal-title":"Oncologist"},{"key":"10.1016\/j.canlet.2026.218803_bib242","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1158\/1078-0432.CCR-21-0426","article-title":"Phase I Trial of Cetuximab, Radiotherapy, and Ipilimumab in Locally Advanced Head and Neck Cancer","volume":"28","author":"Ferris","year":"2022","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.canlet.2026.218803_bib243","doi-asserted-by":"crossref","first-page":"5358","DOI":"10.1158\/1078-0432.CCR-16-2748","article-title":"Phase Ib Pilot Study to Evaluate Reparixin in Combination with Weekly Paclitaxel in Patients with HER-2-Negative Metastatic Breast Cancer","volume":"23","author":"Schott","year":"2017","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.canlet.2026.218803_bib244","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/S1470-2045(16)00078-4","article-title":"Targeting tumour-associated macrophages with CCR2 inhibition in combination with FOLFIRINOX in patients with borderline resectable and locally advanced pancreatic cancer: a single-centre, open-label, dose-finding, non-randomised, phase 1b trial","volume":"17","author":"Nywening","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.canlet.2026.218803_bib245","doi-asserted-by":"crossref","first-page":"3644","DOI":"10.1158\/1078-0432.CCR-24-1821","article-title":"Neoadjuvant BMS-813160, Nivolumab, Gemcitabine, and Nab-Paclitaxel for Patients with Pancreatic Cancer","volume":"31","author":"Grierson","year":"2025","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.canlet.2026.218803_bib246","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-011284","article-title":"Phase 1b\/2 study of BMS-813160, a CCR2\/5 dual antagonist, in combination with chemotherapy or nivolumab in patients with advanced pancreatic or colorectal cancer","volume":"14","author":"Le","year":"2026","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.canlet.2026.218803_bib247","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1186\/s40425-019-0706-x","article-title":"Phase I trial of HuMax-IL8 (BMS-986253), an anti-IL-8 monoclonal antibody, in patients with metastatic or unresectable solid tumors","volume":"7","author":"Bilusic","year":"2019","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.canlet.2026.218803_bib248","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1093\/annonc\/mdx028","article-title":"Phase II study of idelalisib, a selective inhibitor of PI3K\u03b4, for relapsed\/refractory classical Hodgkin lymphoma","volume":"28","author":"Gopal","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.canlet.2026.218803_bib249","doi-asserted-by":"crossref","DOI":"10.1172\/JCI152670","article-title":"Multicenter randomized phase II trial of atezolizumab with or without cobimetinib in biliary tract cancers","volume":"131","author":"Yarchoan","year":"2021","journal-title":"J Clin Invest"},{"key":"10.1016\/j.canlet.2026.218803_bib250","doi-asserted-by":"crossref","DOI":"10.1158\/1078-0432.CCR-25-4364","article-title":"Phase I trial of Ipatasertib plus Atezolizumab enhances PI3K\/AKT pathway immune responses in solid tumors and refractory glioblastoma","author":"Tiu","year":"2026","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.canlet.2026.218803_bib251","doi-asserted-by":"crossref","first-page":"4239","DOI":"10.2147\/OTT.S136992","article-title":"Safety, pharmacokinetics, and pharmacodynamics of oral omaveloxolone (RTA 408), a synthetic triterpenoid, in a first-in-human trial of patients with advanced solid tumors","volume":"10","author":"Creelan","year":"2017","journal-title":"Onco Targets Ther"},{"key":"10.1016\/j.canlet.2026.218803_bib252","doi-asserted-by":"crossref","first-page":"9801","DOI":"10.1038\/s41467-024-52528-7","article-title":"Entinostat in combination with nivolumab in metastatic pancreatic ductal adenocarcinoma: a phase 2 clinical trial","volume":"15","author":"Baretti","year":"2024","journal-title":"Nat Commun"},{"key":"10.1016\/j.canlet.2026.218803_bib253","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1038\/s43018-024-00729-w","article-title":"Entinostat, nivolumab and ipilimumab for women with advanced HER2-negative breast cancer: a phase Ib trial","volume":"5","author":"Roussos Torres","year":"2024","journal-title":"Nat Cancer"},{"key":"10.1016\/j.canlet.2026.218803_bib254","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1038\/s41591-022-01694-6","article-title":"Nivolumab plus ipilimumab with or without live bacterial supplementation in metastatic renal cell carcinoma: a randomized phase 1 trial","volume":"28","author":"Dizman","year":"2022","journal-title":"Nat Med"},{"key":"10.1016\/j.canlet.2026.218803_bib255","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1001\/jamaoncol.2020.5572","article-title":"Effect of Taxane Chemotherapy With or Without Indoximod in Metastatic Breast Cancer: A Randomized Clinical Trial","volume":"7","author":"Mariotti","year":"2021","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.canlet.2026.218803_bib256","doi-asserted-by":"crossref","DOI":"10.1158\/1078-0432.CCR-26-1124","article-title":"Phase 1 evaluation of patients with newly diagnosed glioblastoma treated with radiation, nivolumab, and IDO1 enzyme inhibitor BMS-986205","author":"Lukas","year":"2026","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.canlet.2026.218803_bib257","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1016\/j.jtho.2022.12.021","article-title":"CD73 Inhibitor Oleclumab Plus Osimertinib in Previously Treated Patients With Advanced T790M-Negative EGFR-Mutated NSCLC: A Brief Report","volume":"18","author":"Kim","year":"2023","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.canlet.2026.218803_bib258","doi-asserted-by":"crossref","first-page":"7018","DOI":"10.1038\/s41467-023-42744-y","article-title":"Paclitaxel plus carboplatin and durvalumab with or without oleclumab for women with previously untreated locally advanced or metastatic triple-negative breast cancer: the randomized SYNERGY phase I\/II trial","volume":"14","author":"Buisseret","year":"2023","journal-title":"Nat Commun"},{"key":"10.1016\/j.canlet.2026.218803_bib259","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1007\/s00262-023-03430-6","article-title":"First-in-human study of oleclumab, a potent, selective anti-CD73 monoclonal antibody, alone or in combination with durvalumab in patients with advanced solid tumors","volume":"72","author":"Bendell","year":"2023","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.canlet.2026.218803_bib260","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-005802","article-title":"Anti-CD73 antibody activates human B cells, enhances humoral responses and induces redistribution of B cells in patients with cancer","volume":"10","author":"Miller","year":"2022","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.canlet.2026.218803_bib261","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1007\/s10637-016-0420-1","article-title":"First-in-human study of the antibody DR5 agonist DS-8273a in patients with advanced solid tumors","volume":"35","author":"Forero","year":"2017","journal-title":"Invest New Drugs"},{"key":"10.1016\/j.canlet.2026.218803_bib262","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/s10549-011-1889-0","article-title":"Phase 2 study of neoadjuvant treatment with NOV-002 in combination with doxorubicin and cyclophosphamide followed by docetaxel in patients with HER-2 negative clinical stage II-IIIc breast cancer","volume":"132","author":"Montero","year":"2012","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.canlet.2026.218803_bib263","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1186\/s12885-022-09258-0","article-title":"Rituximab in combination with gemcitabine plus cisplatin in patients with recurrent and metastatic head and neck squamous cell carcinoma: a phase I trial","volume":"22","author":"Hsieh","year":"2022","journal-title":"BMC Cancer"},{"key":"10.1016\/j.canlet.2026.218803_bib264","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.2147\/JHC.S416933","article-title":"Efficacy of Invariant Natural Killer T Cell Infusion Plus Transarterial Embolization vs Transarterial Embolization Alone for Hepatocellular Carcinoma Patients: A Phase 2 Randomized Clinical Trial","volume":"10","author":"Guo","year":"2023","journal-title":"J Hepatocell Carcinoma"},{"key":"10.1016\/j.canlet.2026.218803_bib265","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.lungcan.2023.02.020","article-title":"Safety and efficacy of second-line metronomic oral vinorelbine-atezolizumab combination in stage IV non-small-cell lung cancer: An open-label phase II trial (VinMetAtezo)","volume":"178","author":"Vergnenegre","year":"2023","journal-title":"Lung Cancer"},{"key":"10.1016\/j.canlet.2026.218803_bib266","doi-asserted-by":"crossref","first-page":"oyag140","DOI":"10.1093\/oncolo\/oyag140","article-title":"Phase 2 study of cabozantinib (XL184) with nivolumab and ipilimumab for the treatment of poorly differentiated neuroendocrine carcinomas (ETCTN10315)","volume":"31","author":"Mandl","year":"2026","journal-title":"Oncologist"},{"key":"10.1016\/j.canlet.2026.218803_bib267","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/j.cell.2017.12.026","article-title":"LXR\/ApoE activation restricts innate immune suppression in cancer","volume":"172","author":"Tavazoie","year":"2018","journal-title":"Cell"}],"container-title":["Cancer Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383526005677?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383526005677?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T19:49:08Z","timestamp":1787860148000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304383526005677"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":267,"alternative-id":["S0304383526005677"],"URL":"https:\/\/doi.org\/10.1016\/j.canlet.2026.218803","relation":{},"ISSN":["0304-3835"],"issn-type":[{"value":"0304-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Myeloid-derived suppressor cells in the tumor microenvironment: cellular crosstalk, immunosuppressive effects, and therapeutic targets.","name":"articletitle","label":"Article Title"},{"value":"Cancer Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canlet.2026.218803","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"218803"}}